立体定向体部放疗联合靶向药物治疗转移性肾癌的研究进展

doi:10.11904/j.issn.1002-3070.2022.06.017

摘要/Abstract

摘要： 立体定向体部放疗(Stereotactic body radiotherapy,SBRT)是近年来放疗取得的一个突破性进展,具有分次剂量高、生物学效应高、分割次数少等优势,可显著提高肾癌的放疗敏感性。分子靶向治疗显著延长了部分患者的无进展生存期和总生存期,但在大多数情况下产生全身用药的耐药性仍不可避免。近年来,SBRT联合靶向药物治疗转移性肾癌初步显示了有效性和安全性,有可能成为一种更有效的治疗方案。本文针对SBRT联合靶向药物治疗转移性肾癌研究进展进行综述。

关键词: 转移性肾癌, 立体定向体部放疗, 靶向药物

Abstract: Stereotactic body radiotherapy(SBRT)is a breakthrough in radiotherapy in recent years.It has the advantages of high fractionated dose,high biological effect and less segmentation times,which can significantly improve the radiosensitivity of renal cell carcinoma.Molecular targeted therapy has greatly extended the progression-free survival and overall survival of some patients,but systemic drug resistance is inevitable in most cases.In recent years,the combination of SBRT and targeted drugs in the treatment of metastatic renal cell carcinoma has initially shown its effectiveness and safety,which may become a more effective treatment scheme.This article reviews the research progress in the treatment of metastatic renal cell carcinoma with SBRT combined with targeted drugs.

Key words: Metastatic renal cell carcinoma, Stereotactic body radiotherapy, Targeted drugs

中图分类号:

R737.11

李浩, 张鹤骞, 高佳宁, 滕立臣. 立体定向体部放疗联合靶向药物治疗转移性肾癌的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 580-584.

LI Hao, ZHANG Heqian, GAO Jianing, TENG Lichen. Research progress of stereotactic body radiotherapy combined with targeted drugs in metastatic renal cell carcinoma[J]. Journal of Practical Oncology, 2022, 36(6): 580-584.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.06.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I6/580

参考文献

1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2020[J].CA Cancer J Clin,2020,70(1):7-30.
2 Fusco V,Parisi S,d′Andrea B,et al.Role of radiotherapy in the treatment of renal cell cancer:updated and critical review[J].Tumori,2017,103(6):504-510.
3 Motzer RJ,Hutson TE,Cella D,et al.Pazopanib versus sunitinib in metastatic renal-cell carcinoma[J].N Engl J Med,2013,369(8):722-731.
4 Motzer RJ,Penkov K,Haanen J,et al.Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J].N Engl J Med,2019,380(12):1103-1115.
5 Rini BI,Plimack ER,Stus V,et al.Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J].N Engl J Med,2019,380(12):1116-1127.
6 何立儒,董培,高剑铭,等.今非昔比:放疗在肾癌中的发展现况[J].现代泌尿外科杂志,2022,27(1):1-6.
7 孙明亮,徐建宇,徐向英.早期非小细胞肺癌立体定向放疗的相关研究[J].实用肿瘤学杂志,2018,32(1):53-56.
8 Parashar B,Patro KC,Smith M,et al.Role of radiation therapy for renal tumors[J].Semin Intervent Radiol,2014,31(1):86-90.
9 Escudier B,Porta C,Schmidinger M,et al.Renal cell carcinoma:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2019,30(5):706-720.
10 Brotherston D,Poon I.SBRT treatment of multiple recurrent auricular squamous cell carcinomas following surgical and conventional radiation treatment failure[J].Cureus,2015,7(9):e325.
11 Dengina N,Tsimafeyeu I,Mitin T.Current role of radiotherapy for renal-cell carcinoma:review[J].Clin Genitourin Cancer,2017,15(2):183-187.
12 Yamamoto T,Kawasaki Y,Umezawa R,et al.Stereotactic body radiotherapy for kidney cancer:a 10-year experience from a single institute[J].J Radiat Res,2021,62(3):533-539.
13 徐楚潇,马潞林.肾癌立体定向体部放疗的研究进展[J].现代泌尿外科杂志,2020,25(1):79-83.
14 Rockwell S,Dobrucki IT,Kim EY,et al.Hypoxia and radiation therapy:past history,ongoing research,and future promise[J].Curr Mol Med,2009,9(4):442-458.
15 Jackson RK,Liew LP,Hay MP.Overcoming radioresistance:small molecule radiosensitisers and hypoxia-activated prodrugs[J].Clin Oncol(R Coll Radiol),2019,31(5):290-302.
16 Siva S,Kothari G,Muacevic A,et al.Radiotherapy for renal cell carcinoma:renaissance of an overlooked approach[J].Nat Rev Urol,2017,14(9):549-563.
17 Hui Z,Tretiakova M,Zhang Z,et al.Radiosensitization by inhibiting STAT1 in renal cell carcinoma[J].Int J Radiat Oncol Biol Phys,2009,73(1):288-295.
18 Zhu H,Wang Z,Xu Q,et al.Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy[J].Cancer Biol Ther,2012,13(6):401-407.
19 Xu C,Zhao X,Ju X,et al.Short-term outcomes and clinical efficacy of stereotactic body radiation therapy(SBRT)for oligometastases of prostate cancer in China[J].Front Oncol,2022,12:879310.
20 Franzese C,Franceschini D,Di Brina L,et al.Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma[J].J Urol,2019,201(1):70-75.
21 Stenman M,Sinclair G,Paavola P,et al.Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014[J].Radiother Oncol,2018,127(3):501-506.
22 Wang CJ,Christie A,Lin MH,et al.Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases[J].Int J Radiat Oncol Biol Phys,2017,98(1):91-100.
23 王萍,范莉,田梅.放射性皮肤损伤机制的研究进展[J].中国辐射卫生,2022,31(4):524-529.
24 Kepka L,Socha J.Dose and fractionation schedules in radiotherapy for non-small cell lung cancer[J].Transl Lung Cancer Res,2021,10(4):1969-1982.
25 Burkoň P,Slavik M,Kazda T,et al.Stereotactic body radiotherapy-current indications[J].Klin Onkol,2019,32(1):10-24.
26 Timmerman RD,Herman J,Cho LC.Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice[J].J Clin Oncol,2014,32(26):2847-2854.
27 Smith BW,Joseph JR,Saadeh YS,et al.Radiosurgery for treatment of renal cell metastases to spine:a systematic review of the literature[J].World Neurosurg,2018,109:e502-e509.
28 Reddy AV,Mills MN,Liauw SL,et al.Long term control and preservation of renal function after multiple courses of stereotactic body radiation therapy for renal cell carcinoma[J].Can J Urol,2019,26(2):9743-9745.
29 Svedman C,Karlsson K,Rutkowska E,et al.Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney[J].Acta Oncol,2008,47(8):1578-1583.
30 Singh D.Current updates and future perspectives on the management of renal cell carcinoma[J].Life Sci,2021,264:118632.
31 Brown C.Targeted therapy:an elusive cancer target[J].Nature,2016,537(7620):S106-108.
32 Bedke J,Gauler T,Grünwald V,et al.Systemic therapy in metastatic renal cell carcinoma[J].World J Urol,2017,35(2):179-188.
33 Kaelin WG Jr.The von Hippel-Lindau tumour suppressor protein:O₂ sensing and cancer[J].Nat Rev Cancer,2008,8(11):865-873.
34 Pracht M,Berthold D.Successes and limitations of targeted therapies in renal cell carcinoma[J].Prog Tumor Res,2014,41:98-112.
35 Falkowski S.Résistance aux inhibiteurs des tyrosines kinases dans le cancer du rein[J].Bulletin du Cancer,2018,105:S255-S260.
36 Formisano L,Napolitano F,Rosa R,et al.Mechanisms of resistance to mTOR inhibitors[J].Crit Rev Oncol Hematol,2020,147:102886.
37 Michot JM,Bigenwald C,Champiat S,et al.Immune-related adverse events with immune checkpoint blockade:a comprehensive review[J].Eur J Cancer,2016,54:139-148.
38 Mendiratta P,Rini BI,Ornstein MC.Emerging immunotherapy in advanced renal cell carcinoma[J].Urol Oncol,2017,35(12):687-693.
39 Griffin RJ,Williams BW,Wild R,et al.Simultaneous inhibition of the receptor kinase activity of vascular endothelial,fibroblast,and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response[J].Cancer Res,2002,62(6):1702-1706.
40 Zeng J,Baik C,Bhatia S,et al.Combination of stereotactic ablative body radiation with targeted therapies[J].The Lancet Oncology,2014,15(10):e426-e434.
41 Geng L,Donnelly E,McMahon G,et al.Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy[J].Cancer Res,2001,61(6):2413-2419.
42 Ozao-Choy J,Ma G,Kao J,et al.The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies[J].Cancer Res,2009,69(6):2514-2522.
43 Huang Y,Goel S,Duda DG,et al.Vascular normalization as an emerging strategy to enhance cancer immunotherapy[J].Cancer Res,2013,73(10):2943-2948.
44 Dengina N,Mitin T,Gamayunov S,et al.Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma:a prospective multicentre study[J].ESMO Open,2019,4(5):e000535.
45 Miller JA,Balagamwala EH,Angelov L,et al.Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma[J].J Neurosurg Spine,2016,25(6):766-774.
46 Spigel DR,Hainsworth JD,Yardley DA,et al.Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab[J].J Clin Oncol,2010,28(1):43-48.
47 Lordick F,Geinitz H,Theisen J,et al.Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation:report of three cases[J].Int J Radiat Oncol Biol Phys,2006,64(5):1295-1298.

[1]	汪霖综述, 孟祥宁审校. 人类表皮生长因子受体2阳性肿瘤靶向药物研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 266-270.
[2]	彭芳, 陈明. 放疗联合分子靶向药物治疗非小细胞肺癌的研究进展[J]. 实用肿瘤学杂志, 2012, 26(1): 42-48.
[3]	孙婷婷, 白玉贤. 胃癌的分子靶向治疗[J]. 实用肿瘤学杂志, 2011, 25(2): 190-193.
[4]	叶小红, 张沂平. 非小细胞肺癌常见靶向药物的毒副反应研究进展[J]. 实用肿瘤学杂志, 2010, 24(2): 182-185.
[5]	姜明哲综述, 李晓莉审校. 乳腺癌的靶向治疗[J]. 实用肿瘤学杂志, 2008, 22(6): 586-589.